Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.

[1]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[3]  C. Leissinger,et al.  Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.

[4]  N. Lazaridis,et al.  Acquired Hemophilia and Anti-Hu Paraneoplastic Neurologic Syndrome in Small Cell Lung Cancer. , 2017, The American journal of the medical sciences.

[5]  J. McQuade,et al.  Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy , 2017, Journal of Immunotherapy for Cancer.

[6]  S. Nair,et al.  Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. , 2016, The New England journal of medicine.

[7]  C. Mateus,et al.  Hemophilia A induced by ipilimumab. , 2011, The New England journal of medicine.

[8]  T. Gajewski,et al.  Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.

[9]  N. Saijo,et al.  Acquired factor VIII inhibitor in a patient with adenocarcinoma of the lung. , 1992, Japanese journal of clinical oncology.